Capstone Therapeutics (NASDAQ:CAPS – Get Free Report) posted its quarterly earnings results on Wednesday. The company reported ($0.21) EPS for the quarter, FiscalAI reports. Capstone Therapeutics had a negative return on equity of 93.49% and a negative net margin of 45.01%.The company had revenue of $12.64 million for the quarter.
Capstone Therapeutics Trading Up 26.1%
NASDAQ CAPS opened at $0.39 on Thursday. The company has a quick ratio of 0.26, a current ratio of 1.00 and a debt-to-equity ratio of 0.75. Capstone Therapeutics has a 52 week low of $0.26 and a 52 week high of $2.14. The stock has a market capitalization of $5.56 million, a PE ratio of -0.11 and a beta of -1.52. The firm has a 50 day moving average of $0.52 and a two-hundred day moving average of $0.67.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Capstone Therapeutics stock. DRW Securities LLC purchased a new position in shares of Capstone Therapeutics Corp. (NASDAQ:CAPS – Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund purchased 125,422 shares of the company’s stock, valued at approximately $91,000. DRW Securities LLC owned approximately 1.51% of Capstone Therapeutics as of its most recent SEC filing. Institutional investors and hedge funds own 2.55% of the company’s stock.
Analyst Upgrades and Downgrades
Get Our Latest Report on Capstone Therapeutics
About Capstone Therapeutics
Capstone Therapeutics Corp., a biotechnology company, develops novel peptides and other molecules for helping patients with under-served medical conditions in the United States. It develops Apo E mimetic peptide molecule AEM-28 and its analogs that have completed Phase Ia and Phase Ib/IIa clinical trials for lipoprotein metabolism. The company was formerly known as OrthoLogic Corp. and changed its name to Capstone Therapeutics Corp. in May 2010. Capstone Therapeutics Corp. was founded in 1987 and is headquartered in Tempe, Arizona.
Featured Stories
- Five stocks we like better than Capstone Therapeutics
- Freight Boom: The Hormuz Blockade Payday
- The Palantir Paradox—Record Numbers and a Stock That Won’t Cooperate
- TJX Companies Fires on All Cylinders With 9% Revenue Growth
- From Zepbound to Foundayo: Lilly’s Latest Results Support Oral GLP-1 Outlook
Receive News & Ratings for Capstone Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capstone Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
